Last mentioned: Jul 16, 2026
Across the most recent 7 stories covering Merck — 71% positive, 29% neutral sentiment, averaging 7/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.
Source: Yahoo Finance · Mayo Clinic News Network
This page surfaces every story mentioning Merck across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Merck was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |